170 related articles for article (PubMed ID: 25261419)
1. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials.
Shiber S; Yahav D; Avni T; Leibovici L; Paul M
J Antimicrob Chemother; 2015 Jan; 70(1):41-7. PubMed ID: 25261419
[TBL] [Abstract][Full Text] [Related]
2. Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials.
Chen M; Zhang M; Huang P; Lin Q; Sun C; Zeng H; Deng Y
Expert Rev Anti Infect Ther; 2018 Feb; 16(2):111-120. PubMed ID: 29343141
[TBL] [Abstract][Full Text] [Related]
3. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.
Paul M; Silbiger I; Grozinsky S; Soares-Weiser K; Leibovici L
Cochrane Database Syst Rev; 2006 Jan; (1):CD003344. PubMed ID: 16437452
[TBL] [Abstract][Full Text] [Related]
4. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis.
Vardakas KZ; Tansarli GS; Rafailidis PI; Falagas ME
J Antimicrob Chemother; 2012 Dec; 67(12):2793-803. PubMed ID: 22915465
[TBL] [Abstract][Full Text] [Related]
5. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.
Paul M; Lador A; Grozinsky-Glasberg S; Leibovici L
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003344. PubMed ID: 24395715
[TBL] [Abstract][Full Text] [Related]
6. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
7. Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
Muhammed M; Flokas ME; Detsis M; Alevizakos M; Mylonakis E
Open Forum Infect Dis; 2017; 4(2):ofx099. PubMed ID: 28702469
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.
Son SK; Lee NR; Ko JH; Choi JK; Moon SY; Joo EJ; Peck KR; Park DA
J Antimicrob Chemother; 2018 Oct; 73(10):2631-2642. PubMed ID: 29800480
[TBL] [Abstract][Full Text] [Related]
9. Carbapenems vs. alternative β-lactams for the treatment of nosocomial pneumonia: A systematic review and meta-analysis.
O'Donnell JN; Rhodes NJ; Lopez J; Jett R; Scheetz MH
Int J Antimicrob Agents; 2018 Oct; 52(4):451-458. PubMed ID: 29665442
[TBL] [Abstract][Full Text] [Related]
10. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
Paul M; Yahav D; Fraser A; Leibovici L
J Antimicrob Chemother; 2006 Feb; 57(2):176-89. PubMed ID: 16344285
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
13. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.
Vardakas KZ; Voulgaris GL; Maliaros A; Samonis G; Falagas ME
Lancet Infect Dis; 2018 Jan; 18(1):108-120. PubMed ID: 29102324
[TBL] [Abstract][Full Text] [Related]
14. Novel Beta-Lactam/Beta-Lactamase Plus Metronidazole vs Carbapenem for Complicated Intra-abdominal Infections: A Meta-analysis of Randomized Controlled Trials.
Che H; Wang J; Wang R; Cai Y
Open Forum Infect Dis; 2021 Jan; 8(1):ofaa591. PubMed ID: 33511229
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials.
Marcus R; Paul M; Elphick H; Leibovici L
Int J Antimicrob Agents; 2011 Jun; 37(6):491-503. PubMed ID: 21292449
[TBL] [Abstract][Full Text] [Related]
16. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.
Paul M; Benuri-Silbiger I; Soares-Weiser K; Leibovici L
BMJ; 2004 Mar; 328(7441):668. PubMed ID: 14996699
[TBL] [Abstract][Full Text] [Related]
17. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
Goldenberg JZ; Ma SS; Saxton JD; Martzen MR; Vandvik PO; Thorlund K; Guyatt GH; Johnston BC
Cochrane Database Syst Rev; 2013 May; (5):CD006095. PubMed ID: 23728658
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.
Svetitsky S; Leibovici L; Paul M
Antimicrob Agents Chemother; 2009 Oct; 53(10):4069-79. PubMed ID: 19596875
[TBL] [Abstract][Full Text] [Related]
20. Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen.
Lodise TP; Yucel E; Obi EN; Watanabe AH; Nathanson BH
J Antimicrob Chemother; 2024 Jan; 79(1):82-95. PubMed ID: 37962080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
